secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001171843-23-002712
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q1 net loss $24.3M ($0.58/sh); 1,244+ patients in Phase 3 simufilam trials
--------------------------------------------------------------------------

- Net loss widened to $24.3M from $17.5M YoY; R&D expense rose to $22.1M on trial costs.
- Cash and equivalents $187.5M, no debt; H1 2023 net cash use guidance reduced to $30-40M from $45-50M.
- Over 1,244 Alzheimer's patients enrolled in Phase 3 program (target ~1,750); enrollment completion expected Q4 2023.
- Phase 2 open-label study showed long-term safety; mild patients had ADAS-Cog improvement vs historical placebo decline.
- Cognition Maintenance Study (randomized withdrawal) results expected Q3 2023; filamin A biological data due Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184323002712/0001171843-23-002712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184323002712/f8k_043023.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-002712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer